Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
XENE · NASDAQ · Pharmaceutical Preparations
Xenon Pharmaceuticals (XENE) · oqro.io/stocks/XENE · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$37.04−0.52 (−1.38%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Yes. Insiders of Xenon Pharmaceuticals (XENE) filed 2 open-market purchases in the last 90 days; the latest was filed on Oct 1, 2026.
Since 2015, Xenon Pharmaceuticals insiders reported 55 open-market purchases and 93 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
No open-market sale by an insider of Xenon Pharmaceuticals (XENE) was filed with the SEC in the last 90 days.
No trade in Xenon Pharmaceuticals (XENE) was disclosed by a member of Congress in the last 12 months.
Xenon Pharmaceuticals's next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−8.0% (−$3.23) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $40.27 on Nov 20, 2025 to $37.04 on Nov 20, 2026 (−8.0%). Disclosed in this range: 2 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 18 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Burnaby.
Last 12 months
−8.0%
Market value
$3.64B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 7.36M shares sold short (7.5% of shares outstanding), +0.2% vs the previous count, 6.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$7.5M
Year ended Dec 31, 2025
Net income, fiscal 2025
−$346M
A loss for the year
Shares outstanding
98.3M
As of Nov 5, 2026
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Insider buying
Largest insider buy since 2015Traded Sep 30 · filed 1 day later
Since the trade −0.4% · S&P 500 −9.6% · to Nov 20
Bought within 2% of the 52-week low, RSI 19, 30% under its 200-day average, 41 points behind the S&P 500 over 3 months
The CEO of Xenon Pharmaceuticals paid $1.12M out of pocket for Xenon Pharmaceuticals shares. 1 other person at Xenon Pharmaceuticals bought some too, in the same month. Shares held went up 151% with this purchase.
Insider buying
Largest insider buy since 2015Traded Sep 30 · filed 1 day later
Since the trade −0.4% · S&P 500 −9.6% · to Nov 20
Bought within 2% of the 52-week low, RSI 19, 30% under its 200-day average, 41 points behind the S&P 500 over 3 months
The CFO of Xenon Pharmaceuticals paid $560K out of pocket for Xenon Pharmaceuticals shares. 1 other person at Xenon Pharmaceuticals bought some too, in the same month.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 18, 2025, XENE is down 8.8% and the index fund is up 4.5%: 13 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much XENE moves
Beta 0.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Insiders of Xenon Pharmaceuticals reported 55 open-market purchases and 93 sales since 2015; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $1.68M2×2 trades | — |
| 2025 | — | $2.21M5×5 trades |
| 2024 | — | $2M11×11 trades |
| 2023 | — | $9.19M19×19 trades |
| 2022 | $20K1×1 trade | $16.1M37×37 trades |
| 2021 | $98K1×1 trade | $871K5×5 trades |
| 2020 | — | $113K2×2 trades |
| 2019 | — | $306K6×6 trades |
| 2017 | $2.76M47×47 trades | — |
| 2016 | $33K4×4 trades | $470K5×5 trades |
| 2015 | — | $197K3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Xenon Pharmaceuticals over the 12 months to Nov 21, 2026: 9 clinical trials.
8 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in major depressive disorder, focal epilepsy, primary generalized tonic-clonic seizures. The ones with the nearest registered primary completion date still ahead:
2 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
FMR LLC
13G · passive · Amended · 11.1M shares · filed Nov 5, 2026
T. Rowe Price Investment Management, Inc.
13G · passive · Up from 8.2% · 10M shares · filed Nov 6, 2026
Polar Capital Holdings Plc
13G · passive · Crossed 5% · 5.02M shares · filed Nov 16, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by software from the filings listed below · Oct 26, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeWritten by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
−$357M
This quarter −$90.6M, a year earlier −$72M
Net debt
—
Debt —, cash $82.6M, at Sep 30, 2026
Net income, last 12 months
−$429M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Revenue and earnings history, 14 fiscal yearsEarnings dates and the stock's moves
2 certified in FY2026 Q3, vs 2 a year earlier. 2 positions in total, median offered wage $137K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Nov 9, 2026
Within the 30 days after it, until Dec 9, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
45%
25 of 55 insider purchases since 2014 came within 30 days after a results announcement
From Xenon Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Xenon Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 27, 2025. Read the filing
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fails to deliver: 44K shares (about $1.6M) were not delivered on time for settlement on Oct 8, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 47.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (31.1% on ATS, 16.0% with other brokers), above its 26-week average of 45.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (12.6%), INTELLIGENT CROSS LLC (9.3%), BIDS ATS (8.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.